Results 141 to 150 of about 13,617 (225)
PENGOBATAN ASMA DENGAN OMALIZUMAB
, 2015 Abstrak. Asma bronkial merupakan salah satu reaksi alergi berupa peradangan (inflamasi) pada saluran pernafasan. asma termasuk dalam reaksi hipersensitifitas tipe 1 yang termediasi oleh IgE. Dalam keadaan normal, IgE dalm serum kadarnya berkisar antara 0,
Novita Andayani
core
Clinical and Translational Science, Volume 19, Issue 6, June 2026.Overview of patient centric microsampling approach for monitoring respiratory biomarkers for treatment optimization. Image created in BioRender. Khan, A. (2026) https://BioRender.com/17jm5cs. ABSTRACT The clinical heterogeneity of respiratory disorders emphasizes the need for personalized approaches to prevention, diagnosis, and therapy.
Ahmar Khan +4 more
wiley +1 more source
, 2008 Immunoglobulin E plays a central role in the pathogenesis of asthma. Omalizumab is a recombinant humanised monoclonal antibody directed against Immunoglobulin E to inhibit the immune system's response to allergen exposure.
G.F. Sferrazza Papa +2 more
core
The role of omalizumab in the treatment of adults with severe allergic asthma
Zdravniški Vestnik, 2013 Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija.
Sabina Škrgat Kristan
doaj
PECU: A multicenter study on pediatric patients with cold‐induced urticaria
Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.Abstract Background Cold‐induced urticaria (ColdU) is a rare chronic inducible urticaria that can cause systemic reactions, including cold‐induced anaphylaxis (ColdA), but pediatric data are limited. The aim of this study was to evaluate the clinical characteristics, comorbidities, management approaches, risk of anaphylaxis, and long‐term course of ...
Betul Gemici Karaaslan +59 more
wiley +1 more source
Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.High BDR (≥10% FEV1) predicts 3‐fold higher odds of poor asthma control in children with moderate‐to‐severe asthma. High BDR links to elevated T2 cytokines (IL‐4, IL‐13) and non‐T2 mediators (IL‐1β, IL‐6, IL‐7, IL‐8, TNF‐α), as well as MMP‐1. BDR offers non‐invasive phenotyping potential to advance personalized asthma management.
Nariman K. A. Metwally +24 more
wiley +1 more source
Pediatric Allergy and Immunology, Volume 37, Issue 6, June 2026.This graphical abstract illustrates the conceptual framework linking rare and common diseases in pediatric allergy and immunology through precision medicine. On the left, rare conditions such as inborn errors of immunity and primary atopic disorders represent well‐defined monogenic models that reveal fundamental mechanisms of immune dysregulation.
Riccardo Castagnoli +26 more
wiley +1 more source
Algorithms of Patient Selection for Allergen Immunotherapy
Allergy, Volume 81, Issue 6, Page 2225-2229, June 2026.
U. Petra Zieglmayer +5 more
wiley +1 more source
Omalizumab in food allergy: Risks and benefits
Omalizumab is approved for the management of immunoglobulin E-mediated food allergy in individuals ages ≥ 1 year. Approval for food allergy followed the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (
Mustafa, S Shahzad, Sokol, Kristin
core +1 more source
Perceived Acquired Resistance to Omalizumab in Obese Patients With Chronic Spontaneous Urticaria
Clinical &Experimental Allergy, Volume 56, Issue 6, Page 671-673, June 2026.
Francisco Martins +3 more
wiley +1 more source